ArticleTranslational lung cancer research2022

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.

Tianqing Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.